Tazopalib 0.25 mg Talazoparib capsules 0.25 mg x 60 capsules

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): MDS/AML has occurred in patients treated with LuciTala, and some cases have even died. Monitor the patient for hematologic toxicity and discontinue if diagnosed with MDS/AML.
• Myelosuppression: LuciTala may affect hematopoietic function and may lead to anemia, neutropenia, and/or thrombocytopenia.
• Embryo-fetal toxicity: LuciTala may cause damage to the fetus. Patients are advised to be aware of their potential risks to the fetus and to take effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) of monotherapy, including laboratory abnormalities, are as follows:
• Hemoglobin decreased, neutropenia, lymphopenia, thrombocytopenia, fatigue, elevated blood sugar, elevated aspartate aminotransferase, elevated alkaline phosphatase, elevated alanine aminotransferase, decreased blood calcium, nausea, headache, vomiting, hair loss, diarrhea, and decreased appetite.

The most common adverse reactions (≥ 10%) in combination with enzalutamide, including laboratory abnormalities, are as follows:
• Hemoglobin decreased, neutropenia, lymphopenia, fatigue, thrombocytopenia, blood calcium decreased, nausea, decreased appetite, decreased blood sodium, decreased blood phosphorus, fractures, decreased blood magnesium, dizziness, increased bilirubin, decreased blood potassium, and impaired taste.